Stocks Health care ACIU
NASDAQ · Health careAC Immune SA (ACIU)
AC Immune SA reported revenue of CHF 3.6M in fiscal 2025, down 86.9% from a year earlier. It posted a net loss of CHF 70.4M. In fiscal 2025 capital spending exceeded operating cash flow by CHF 70.2M. At December 31, 2025 it held CHF 26.8M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 13, 2026.
What AC Immune SA does
AC Immune SA is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACIU.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | CHF 3.6M | -CHF 70.4M | -CHF 0.70 | -CHF 70.2M |
| 2024 | CHF 27.3M | -CHF 50.9M | -CHF 0.51 | CHF 65.3M |
| 2023 | CHF 14.8M | -CHF 54.2M | -CHF 0.64 | -CHF 61.2M |
| 2022 | CHF 3.9M | -CHF 70.8M | -CHF 0.85 | -CHF 74.8M |
| 2021 | CHF 0 | -CHF 73M | -CHF 0.97 | -CHF 68.3M |
| 2020 | CHF 15.4M | -CHF 61.9M | -CHF 0.86 | -CHF 61.2M |
Latest SEC filings
What AC Immune SA has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026
- September 3, 2026
- August 20, 2026
- August 11, 2026
- August 5, 2026
- June 30, 2026
- June 11, 2026
- June 11, 2026
- May 15, 2026
- May 12, 2026
Questions about ACIU
What does AC Immune SA do?
AC Immune SA is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACIU.
Is AC Immune SA profitable?
No. In fiscal 2025 it reported a net loss of CHF 70.4M on revenue of CHF 3.6M.
How much revenue does AC Immune SA make?
In fiscal 2025 AC Immune SA reported revenue of CHF 3.6M. That is 86.9% less than a year earlier.
When did AC Immune SA last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 13, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 23, 2026.
Similar companies
Follow ACIU
Get an email when AC Immune SA files with the SEC: results, executive changes, material agreements and annual reports.
Follow ACIU: get an email when it filesWhere the numbers come from
Financial figures are the values AC Immune SA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.